DKN-01 –
an anti-DKK1


Single agent and combination activity demonstrated in three different tumor types. Well tolerated as monotherapy and in combination with chemotherapy or checkpoint inhibitors.


DKN-01 binds and removes free DKK1 from the TME:

Reduces cell proliferation

Blocks signaling through CKAP4 and PI3K to downregulate Akt

MDSC cells

B-catenin dependent Wnt signaling reprograms MDSCs and reduces immunosuppressive activity

Reduces angiogenesis

Reduces blood vessel formation, upregulates key cytokines, IFNy, IL-15 and IL-33

NK cells

Upregulates NK cell ligands on tumor, production of Granzyme B by activated NK cells

image description

DKN-01 + anti-PD1

DKN-01 stimulates innate
immune system:

Stimulates activity
of NK cells
tumor microenvironment
Upregulates PD-L1 (the target for PD-1 antibodies)

Anti-PD1 stimulate
CD8 T cell adaptive immunity:

Enhances tumor microenvironment for immune cells
to target and clear
the tumor
CD8 T cells
image description

DKK1 expression determined using RNAscope

Chromogenic in situ
hybridization RNAscope

The biopsy sample is stained to identify DKK1 mRNA Pathologist determines histology score (H-Score), measuring DKK1 expression rather than protein itself.

Each red dot is an individual mRNA for DKK1.
Amount of cells and intensity of staining is converted to H-Score.